Lilly Medicine Foundry will research new ways to manufacture medicines. Eli Lilly says in addition to supporting the manufacturing of drugs for clinical trials, manufacturing innovations from the site will be transferred to the company’s other facilities for use in full-scale drug production.
Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Though the case started small, it has gained national attention and more than a dozen states have submitted an amicus brief in support of the Health and Hospital Corporation that operates 78 nursing facilities across Indiana.
After scrapping work requirements for Medicaid eligibility in four states, CMS has added Arizona and Indiana to the list. These requirements have long been controversial, facing litigation and strong opposition, but proponents say they incentivize people to find jobs.
The company announced data on the combination of two antibodies against the SARS-CoV-2 virus, showing significant reductions in viral load compared with placebo. The company has applied for an EUA for LY-CoV555 and will seek an authorization for the combination of that drug with LY-CoV016 next month.
An analyst wrote Wednesday that the combination of Lilly's Olumiant and Gilead's Veklury, or remdesivir, could cost nearly $8,000, a high price tag that could potentially hamper uptake, especially given the availability of cheaper drugs like dexamethasone.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company said that patients receiving LY-CoV555 at the 2,800mg dose showed a lower rate of hospitalization and emergency room visits than those on placebo. However, the other dose levels of the drug did not reach the viral load primary endpoint. An analyst called the data "mixed but constructive."
Amplified Sciences emerged as the winner of the diagnostics track for the MedCity INVEST conference's Pitch Perfect contest with PanCystPro, the test it is developing to address the problems encountered when determining whether pancreatic cysts are cancerous.
The company said it had initiated the Phase III study of Olumiant, one of multiple JAK inhibitors that are being tested to find if they can mitigate the cytokine storm associated with Covid-19's worst complications.
The agency granted accelerated approval to Retevmo in RET fusion-positive non-small-cell lung cancer and thyroid cancer and RET-mutated medullary thyroid cancer. The company is mounting a virtual rollout effort as sales staff are grounded due to the Covid-19 pandemic, an exec said.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The Adaptive Covid-19 Treatment Trial will include several investigational therapies for Covid-19, including Lilly's Olumiant, investigated for efficacy against inflammation caused by the disease.
The drugmaker said it would delay new study starts and also enrollments in ongoing studies due to the strain the pandemic is putting on clinical trial sites. However, patients already enrolled in trials can continue treatment. Bristol-Myers Squibb said it would continue to assess trial operations.
The California-based dermatology company's lead product candidate is a Phase III monoclonal antibody being developed for a type of eczema. Another company, Denmark-based LEO Pharma, has a Phase III drug in the same class for the same disease.
The trial is the second Phase III study of the RET inhibitor selpercatinib, which Lilly acquired when it bought Loxo Oncology at the beginning of this year for $8 billion.
Lilly, which acquired Loxo in January for $8 billion, said the new organization, dubbed Loxo Oncology at Lilly, would have responsibility for discovery research across therapeutic modalities, clinical development and regulatory affairs.